New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Amgen Inc.

AMGN

Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.

Revenue
+8.45%
EPS
+19.4%
Free cash flow
−14.0%
Total debt
−1.06%

Quarter to September 2026, against a year earlier

439.53 0.73 +0.17%
Market cap
$237.4B
P/E
25.2×
Fwd P/E FY26e
24.0×
Dividend yield
2.84%
F-score
7/9
ROIC
14.3%
Net debt / EBITDA
2.9×
Payout ratio
0.7×

Amgen Inc. (AMGN) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by regions, and margins
U.S. 26,419 71.89%
ROW 10,332 28.11%
Gross margin 67.25%
Operating margin 24.71%
Pre-tax margin 24.42%

Revenue by product or service $m

Line FY2021 FY2020 FY2019 FY2018 FY2017 FY2016
Other products 5,710 5,374 4,743 5,572 2,583 3,158
ENBREL 4,465 4,996 5,226 5,014 5,433 5,965
Prolia 3,248 2,763 2,672 2,291 1,968 1,635
Otezla 2,249 2,195 178 0 — —
XGEVA 2,018 1,899 1,935 1,786 1,575 1,529
Other revenues 1,682 1,184 1,158 1,214 1,054 1,099
Aranesp 1,480 1,568 1,729 1,877 2,053 2,093
Repatha 1,117 887 661 550 — —
KYPROLIS 1,108 1,065 1,044 968 835 —
Nplate 1,027 850 795 — — —
Vectibix 873 — — — — —
EVENITY 530 350 — — — —
BLINCYTO 472 — — — — —
KRYSTEXXA 0 — — — — —
TEPEZZA 0 — — — — —
Neulasta — 2,293 3,221 4,475 4,534 4,648
Sensipar Mimpara — — — — 1,718 1,582
Epogen — — — — 1,096 1,282
Product sales 24,297 24,240 22,204 22,533 21,795 21,892
Revenue 25,979 25,424 23,362 23,747 22,849 22,991

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
U.S. 26,419 23,863 19,806 18,595 18,194 18,496 17,224 18,358 18,029 18,326 17,167 15,396 14,480 13,415 11,985
ROW 10,332 9,561 8,384 7,728 7,785 6,928 6,138 5,389 4,820 4,665 4,495 4,667 4,196 3,850 3,597
Revenue 36,751 33,424 28,190 26,323 25,979 25,424 23,362 23,747 22,849 22,991 21,662 20,063 18,676 17,265 15,582

Operating figures as reported in each quarter’s results release or filing

Figure Quarter Latest A year before Change
BLINCYTO volume growth Q2 FY2026 16.0% — —
Nplate volume growth Q2 FY2026 13.0% — —
PAVBLU volume growth Q3 FY2026 71.0% 66.0% —
Repatha volume growth Q1 FY2026 35.0% 41.0% —
TEPEZZA volume growth Q2 FY2026 6.00% 6.00% —
TEZSPIRE volume growth Q1 FY2026 32.0% — —
Unit volume growth Q1 FY2026 9.00% 14.0% —

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.